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AhomodimericcomplexofHLA-Gonnormaltrophoblast
cells modulates antigen-presenting cells via LILRB1
Richard Apps, Lucy Gardner, Andrew M. Sharkey, Nick Holmes and
Ashley Moffett
Department of Pathology, Cambridge University, Cambridge, UK
In healthyindividuals, the non-classical MHC molecule HLA-G is onlyexpressed on fetal
trophoblastcellsthatinvadethedeciduaduringplacentation.Weshowthatasignificant
proportion of HLA-G at the surface of normal human trophoblast cells is present as a
disulphide-linked homodimer of the conventional b2m-associated HLA-I complex.
HLA-G is a ligand for leukocyte immunoglobulin-like receptors (LILR), which bind
much more efficiently to dimeric HLA-G than to conventional HLA-I molecules. We find
that a LILRB1-Fc fusion protein preferentially binds the dimeric form of HLA-G on
trophoblast cells. We detect LILRB1 expression on decidual myelomonocytic cells;
therefore, trophoblast HLA-G may modulate the function of these cells. Co-culture with
HLA-G
+ cells does not inhibit monocyte-deriveddendritic cell up-regulation of HLA-DR
and costimulatory molecules on maturation, but did increase production of IL-6 and
IL-10. Furthermore, proliferation of allogeneic lymphocytes was inhibited by HLA-G
binding to LILRB1/2 on responding antigen-presenting cells (APC). As HLA-G is the
only HLA-I molecule that forms b2m-associated dimers with increased avidity for
LILRB1, this interaction could represent a placental-specific signal to decidual APC. We
suggest that the placenta is modulating maternal immune responses locally in the
uterus through HLA-G, a trophoblast-specific, monomorphic signal present in almost
every pregnancy.
See accompanying commentary: http://dx.doi.org/10.1002/eji.200737515
Introduction
HLA-G is a non-classical HLA class I (HLA-I) molecule,
selectively expressed in healthy individuals by fetal
placental trophoblast cells that invade maternal uterine
tissues during placentation [1–4]. HLA-G is encoded in
the MHC on chromosome 6 and displays a typical HLA-I
structure, including association with b2m and peptide.
Unusual features of HLA-G include absence of an
endosomal recycling motif, leading to a prolonged cell
surface half life [5]. Minimal polymorphism [6, 7], an
endoplasmic reticulum retrieval mechanism [8], and
the structure of the peptide-binding groove [9]
contribute to a restricted peptide repertoire in vivo
[10]. These characteristics argue against a role for
HLA-G as a conventional HLA-I molecule presenting
pathogen-derived peptides to T cells. The functions of
HLA-G are not clear, although restricted expression to
extravillous trophoblast (EVT) cells at the maternal-
fetal interface suggests a role in normal pregnancy.
Fetal EVT cells invading the decidua and myometrium
come into close contact with maternal uterine leuko-
cytes that, in early gestation, are predominantly
composed of NK cells, as well as myelomonocytic cells
and some T cells [11].
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myelomonocytic cells derived from peripheral blood.
The NK cell receptor is KIR2DL4, a member of the killer
immunoglobulin-like receptor (KIR) family. NK cells are
reported to endocytose HLA-G into KIR2DL4-containing
compartments, and the subsequent interactions mod-
ulate NK cell cytokine secretion [12]. LILRB1 and
LILRB2 are inhibitory receptors of the leukocyte
immunoglobulin-like receptor (LILR) family which are
mainly expressed by DC and macrophages [13]. LILRB1
and B2 bind most HLA-I molecules [13–15], but the
highest affinity is for HLA-G [16].
Recently, it was discovered that HLA-G can exist as a
dimer in addition to the conventional heterotrimeric
HLA-I molecule conformation. Dimers of HLA-G were
first described with recombinant protein in vitro [17],
then later observed on the surface of both transfected
cells [17, 18] and the choriocarcinoma cell line JEG-3
[19]. The HLA-G dimer is linked by disulphide-bonding
between cysteine 42 residues of the heavy chain
a1 domain, an exposed extracellular cysteine not
involved in intramolecular Ig superfamily domain
formation [18, 20]. Comparison with other HLA-I gene
sequences shows that a cysteine residue at this position
is unique to HLA-G [18]. Amongst other primates,
cysteine 42 is conserved in the MHC-G genes of
chimpanzees and gorillas that are also non-polymorphic
andpresumablyactasfunctionalhomologues.However,
in the orang-utans, Old and New World monkeys where
MHC-G orthologues function as classical MHC-I mole-
cules or are pseudogenes [21], cysteine 42 is substituted
to a serine which has been shown to abrogate
dimerisation [9, 18].
The outstanding questions are whether these HLA-G
dimers are formed in vivo on normal trophoblast cells
and what their function might be at the maternal-fetal
interface. We now show that a significant proportion of
the HLA-G present on the surface of normal first-
trimester trophoblast cells exists as a dimer. This
complex is a homodimer of two conventionally b2m-
associated HLA-G molecules. We demonstrate LILRB1
andB2expressionbydecidualmyelomonocyticcellsand
show that a LILRB1-Fc fusion protein preferentially
binds to the dimeric form of HLA-G on normal
trophoblast cells. Therefore, HLA-G dimers can provide
a trophoblast-specific signal to decidual myelomonocy-
tic leukocytes via LILRB1. We present evidence that this
interaction leads to modulation of dendritic cell (DC)
function and suppression of allogeneic lymphocyte
proliferation. In this way, HLA-G potentially modifies
the maternal local immune response to fetal trophoblast
cells.
Results
HLA-G forms a disulphide-linked homodimer of
the conventional, b2m-associated HLA class I
complex
To detect HLA-G dimers, surface proteins of 721.221
cells transfected with HLA-G1 cDNA were biotinylated
and immunoprecipitated with a panel of HLA-I-reactive
antibodies. HLA-G-specific MEM-G/11, 87G and G233
recognise the b2m-associated class I structure. W6/32 is
also conformationally dependant but binds all HLA-I
molecules. The immunoprecipitated complexes were
first analysed by denaturing reducing PAGE, followed by
Western blotting for biotin-labelled surface proteins. As
expected, both HLA-G-specific and pan-class I antibo-
dies detected an HLA-G band at 39 kDa, as well as co-
immunoprecipitating the 13.7-kDa b2m molecule
(Fig. 1A). However, when analysed under denaturing
but non-reducing conditions, an additional 80-kDa band
appears, indicating that some of the HLA-G is present as
a disulphide-linked homodimer (Fig. 1B). Densitometry
measurements of complexes detected by G233, MEM-G/
11, W6/32 and BBM.1 estimate that 40% of the HLA-G
molecules are in the dimeric form. HLA-G dimerisation
may alter or obscure the 87G epitope because this
antibody preferentially binds the monomeric form of
HLA-G comparedtootherantibodies inthe panel. Under
non-reducing conditions, both 39- and 80-kDa bands
canbeco-immunoprecipitatedbytheanti-b2mantibody,
BBM.1, indicating that the HLA-G dimers are b2m
associated (Fig.1B). Therefore, HLA-G dimers are of the
conventional class I complex and not free heavy chains
as described previously for HLA-B27 [22]. All these
experiments were repeated with 721.221 cells trans-
fected with genomic HLA-G (as opposed to cDNA) and
the rodent cell line, Ltk, transfected with human b2m
and HLA-G with similar results (not shown).
The characteristics of HLA-G, when expressed by a
trophoblast cell line, were investigated using the
choriocarcinoma cell line, JEG-3. This is similar to
normal EVT in that it expresses HLA-C, HLA-G and
HLA-E whilst lacking HLA-A and HLA-B [10, 23, 24].
Under reducing conditions, an HLA-G band at 39 kDa,
with an additional 45-kDa molecule, was detected by
W6/32 (Fig.1C). The 45-kDa species was confirmed as a
classical HLA-I molecule by immunoprecipitation with
T 149 and B1.23.2, antibodies specific for HLA-C on
these cells (Fig. 1D, E). In contrast to the findings with
HLA-G transfectants, no 80-kDa band was observed
under non-reducing conditions unless the blot was
overexposed to the point that significant background
staining was apparent (Fig. 1D, E). Densitometry
measurements suggest that less than 10% of the HLA-G
molecules are dimerised. Thus, the conventional
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a finding consistent with previous reports [17, 19].
The dimeric HLA-G complex is expressed at the
surface of normal trophoblast cells
The outstanding question is whether the dimeric form of
HLA-G is present on the surface of normal trophoblast
cells. Cells isolated from normal first-trimester placen-
tae, in which only trophoblast cells have been shown to
express HLA-G [25], were surface biotinylated and
immunoprecipitated as before. Immunoprecipitation
with HLA-G-specific antibodies detected 80-kDa dimeric
HLA-G as well as the conventional 39-kDa form under
non-reducing conditions (Fig. 1G). In contrast, the
80-kDa species was not seen in reducing PAGE (Fig.1F).
By densitometry, 40% of the HLA-G molecules appear to
be in the dimeric complex, although the mAb 87G
displays a greater bias tothe monomer as before. W6/32
and BBM.1 antibodies immunoprecipitated both the
monomericanddimericformsofHLA-G,andthe45-kDa
HLA-C molecule was also expressed by normal tropho-
blast cells [23, 24]. As with JEG-3, HLA-C-specific
antibodies confirm the identity of the bands in this
doublet (Fig. 1F, G).
To confirm that the 80-kDa complex consists of
homodimers of HLA-G molecules and not of hetero-
dimers of different HLA-I molecules, or is a cross-
reaction of the Western reagents with an unrelated
80-kDa protein, two-dimensional (2D)-PAGE was per-
formed. Surface-labelled HLA-G was specifically im-
munoprecipitated from transfectants (Fig. 1H) and
trophoblast (Fig. 1J) with the mAb G233. Non-reducing
PAGE in the horizontal dimension resolved the 80-kDa
complex, 39-kDa conventional HLA-G and 13.7-kDa
b2m. After reduction on the gel followed by reducing
PAGE in the vertical dimension, the previously 80-kDa
species migrated the same distance as conventional
39-kDa HLA-G. This confirms that the 80-kDa species is
a disulphide-linked homodimer of the 39-kDa HLA-G
molecule.
To summarise, these results show that HLA-G can
form disulphide-linked homodimers that are b2m
associated and that a significant proportion of the
HLA-G molecules at the surface of normal trophoblast
cells in vivo are present in this dimeric conformation.
Similar results were obtained for HLA-G expressed by
transfected 721.221and Ltk cells. Preferentialbindingof
87G to the monomer in both transfectants and
trophoblast cells suggests that the dimer has a similar
conformation in both contexts, and therefore these
transfectants represent a good model of HLA-G as
displayed at the surface of the trophoblast. In contrast,
HLA-G is found on the surface of the cell line, JEG-3,
predominantly as the conventional monomeric class I
complex.
Figure 1. HLA-G is present on the surface of normal trophoblast cells as a disulphide-linked homodimer of the conventional b2m-
associated class I complex. 721.221 + HLA-G1 transfectants (A, B), JEG-3 cell line (C–E) and trophoblast (F, G) were surface
biotinylated,immunoprecipitatedwith theindicatedantibodies andresolved byreducing(A, C,F) ornon-reducing(B, D,E, G) PAGE
before Western blotting with streptavidin-HRP. All were exposed for less than 1 min, with the exception of (E) which was exposed
for 10 min. Complexes immunoprecipitated with G233 from 721.221 HLA-G
+ transfectants (H) and trophoblast (J) were also
analysed by 2D-PAGE. These gels are representative of at least three different experiments for each cell type, using a total of
20 pooled samples for trophoblast cells. Images in this figure include lanes from several gels.
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homodimer
We also investigated whether the two soluble forms of
HLA-G form dimers. Full-length membrane-bound HLA-
G1 molecules can be shed intact or cleaved from the
surface by metalloproteinase activity [26, 27]. Also, a
splice variant, HLA-G5, retains intron 4, introducing a
premature stop codon before the transmembrane
domain [28]. Both of these soluble forms of HLA-G
were investigated by immunoprecipitation with mAb
G233 and W6/32 from culture supernatant of 721.221
cells transfected with either HLA-G1 or HLA-G5 cDNA.
Immunoprecipitated complexes were analysed by redu-
cing or non-reducing PAGE and detected on a Western
blot with the HLA-G-specific mAb MEM-G/1. Under
reducing conditions, secreted HLA-G5 was detected at
*37 kDa, as expected (Fig. 2A). A soluble HLA-G band
was immunoprecipitated from supernatants of HLA-G1-
transfected cells, but this was at much lower concentra-
tion and only detected in 30-fold concentrated samples
(Fig. 2B). We looked for the presence of dimers using
non-reducing conditions and found that a small
proportion of HLA-G5 was present as a dimer, using
both G233 (Fig. 2C) and W6/32 mAb (not shown). This
confirms that soluble HLA-G can form a disulphide-
linkedhomodimer of the b2m-associated class I complex
similarly to the transmembrane molecule. Immunopre-
cipitations were repeated using concentrated super-
natant of cultured primary trophoblast and pre-
implantation embryos, but no soluble HLA-G1 or
HLA-G5 was detected (Fig. 2B). In conclusion, the
HLA-G5 soluble splice variant of HLA-G can exist as a
dimer identically to HLA-G1 at the cell surface.
However, no soluble forms of HLA-G were detected in
vivo.
Artefactual multimerisation can occur due to in-
complete denaturation under non-reducing conditions
permitting hydrophobic associations. However,
cysteine 42 substitution [18] and the dimer crystal
structure [20] have confirmed that HLA-G homodimers
are disulphide linked. Cytoplasmic tail cysteine residues
have also been observed to mediate post-lysis dimerisa-
tion of classical HLA-I molecules when released from the
reducing intracellular environment [29]. To avoid post-
lysis disulphide bond formation, in our experiments a
lysis buffer containing the alkylating agent iodoaceta-
mide was used that prevents de novo disulphide bond
formation between HLA-I molecules [30]. In addition,
the HLA-G sequence lacks cytoplasmic cysteine residues
and we have also shown that the soluble HLA-G5 splice
variant product forms dimers (Fig. 2). We note that the
Figure 2. Soluble HLA-G can also exist as a disulphide-linked homodimer of the conventional b2m-associated class I complex.
Soluble HLA-G molecules were immunoprecipitated with the indicated antibodies from supernatants of 721.221 cells transfected
with HLA-G1 or HLA-G5 cDNA compared to untransfected cells. The JEG-3 cell line, isolated primary trophoblast, or pre-
implantation embryo culture supernatants were also immunoprecipitated compared to unconditioned medium. Precipitated
complexes were separated by reducing (A, B) or non-reducing PAGE (C) and detected by Western blotting with biotinylated mAb
MEM-G/1 followed by streptavidin-HRP. HLA-G1
+ transfectant, JEG-3 and trophoblast culture supernatants were concentrated
30 times before immunoprecipitation. Gels are representative of four independent experiments. The image in (C) includes lanes
from separate gels.
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This is likely to be an artefact due to residual tertiary
conformation under non-reducing conditions stearically
hindering access of streptavidin-HRP to biotinylated
residues. Reprobing of blots with anti-b2mm A b
confirmed that all light chain was at 13.7 kDa (not
shown) and weaker bands from some biotinylated
molecular weight markers also occurred under non-
reducing conditions (Fig.1). We did not investigate free
heavychains of HLA-G, which have been observed at the
surface of transfectants [19], due to the lack of an
antibody recognising free heavy chains that is specific
for HLA-G in vivo [31].
LILRB1, an HLA class I molecule receptor,
is expressed by decidual leukocytes
HLA-G binds to members of the LILR family, LILRB1 and
B2 [13, 14]. Although these receptors bind a broad
spectrum of HLA-I alleles, they have a higher affinity for
HLA-G [16], particularly in its dimeric form [18, 20].
Therefore, we investigated LILRB1 and B2 expression by
decidual leukocytes. Two different antibodies were used
for both receptors. Maternal decidual leukocytes were
isolated from first-trimester pregnancies and identified
as T cells (CD3), NK cells (CD56) and DC or
macrophages (HLA-DR) [32], followed by staining for
LILR expression. LILRB1 was detected on all DC and
macrophages (Fig. 3A), as well as 20% of NK cells
(Fig. 3D) and 10% of T cells (Fig. 3G). Expression of
LILRB2 was restricted to DC and macrophages (Fig. 3A,
E, H). LILRB2 is expressed more strongly on peripheral
than decidual myelomonocytic cells, whereas LILRB1
appears to predominate in the decidua (Fig. 3A, B).
LILRB1-Fc fusion protein preferentially binds the
dimeric form of HLA-G in vivo
Predominant expression of LILRB1 by decidual leuko-
cytes suggests that this receptor may be particularly
important in the recognition of trophoblast HLA-I
molecules. To investigate this possibility, we studied
binding of a LILRB1-Fc fusion protein to cells expressing
HLA-G. As predicted, LILRB1-Fc bound to 721.221 and
Ltk cells transfected with HLA-G (Fig. 4E, F). The level
of binding correlated with HLA-G expression
(Fig. 4A, B) and the specificity was demonstrated by
blocking with mAb to LILRB1 (M401) and W6/32 which
is known to block LILRB1 binding to HLA-I molecules
[33] (Fig. 4J, K). HLA-G-specific mAb do not bind
epitopes blocking LILRB1 binding. To detect LILRB1-Fc
binding to primary trophoblast preparations, it was
necessary to first label contaminating leukocytes
expressing FccR with lin-FITC, leaving trophoblast
and stromal cells in the FITC-negative quadrants
(Fig. 4N, O). A gate around these cells shows that the
level of HLA-G was less abundant at the surface of
normal trophoblast than transfectants (Fig. 4A, B, D).
Despite this, binding of the LILRB1-Fc fusion protein to
trophoblast cells could still be demonstrated and was
blocked by mAb to LILRB1 or HLA-I (Fig. 4H, M, N, O).
Interestingly, no binding of LILRB1-Fc to JEG-3 cells
was detected (Fig. 4G, L) even though these cells
showed higher levels of HLA-G expression than
trophoblast cells (Fig. 4C, D). The failure to detect
binding to JEG-3 cells, which display HLA-C, HLA-E and
mainly monomeric HLA-G, suggests that LILRB1-Fc
preferentially binds the dimeric form of HLA-G and not
conventional HLA-I molecules.
To test this, the LILRB1-Fc fusion protein was used to
immunoprecipitate surface-labelled proteins from
HLA-G-transfected and primary trophoblast cells
(Fig. 5). As before, the G233 mAb detects both
monomeric and dimeric HLA-G, with *40% of HLA-G
molecules in the dimeric form. The LILRB1-Fc fusion
protein strongly bound the dimeric form of HLA-G,
Figure 3. LILRB expression by decidual leukocytes. Decidual (A)
orperipheral (B)leukocyteswereidentifiedasmyelomonocytic
cells by forward/side scatter and HLA-DR
+ gates and stained
with anti-LILRB1 (dark line), anti-LILRB2 (grey line) or isotype
control antibodies (filled histogram). Decidual CD56
+ (C–E) or
CD3
+ (F–H) lymphocytes were stained with isotype control
(C, F), anti-LILRB1 (D, G) and anti-LILRB2 (E, H) antibodies.
These results from decidual leukocytes are representative of
seven different experiments using decidua pooled from
17 samples. Similar results for both LILRB1 and 2 were
observed with two different antibodies. The apparently higher
isotype control mAb staining of T cells compared to NK cells
results from inclusion of more cells in plots demonstrating
T cell staining,dueto theirlowfrequency indecidualleukocyte
populations.
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the 45-kDa classical HLA-C molecule expressed by
trophoblast cells was not seen at all. These bands were
confirmed to be specific for an interaction of LILRB1
with HLA-G because they were not precipitated from
untransfected 721.221 cells or by an IgG1-Fc fragment.
That LILRB1-Fc predominantly binds to dimeric rather
than monomeric HLA-G at the surface of HLA-G
transfectants and normal trophoblast cells suggests that
this is likely tobethemajor interaction occurring in vivo.
Monocyte-derived DC activated in the presence of
HLA-G demonstrate altered cytokine production
Given the high-affinity interaction of HLA-G dimers with
LILRB1 and the expression of this receptor by all
decidual HLA-DR
+ cells, we next investigated whether
HLA-G appeared to have any functional effect on DC.
Due to the difficulty in obtaining sufficient HLA-DR
+
cells from the decidua that are not activated by the
isolation procedure [32], we used monocyte-derived DC
(MDDC) generated in vitro. MDDC were prepared from
peripheral blood, and their response to a maturation
stimulus was observed in co-culture with cells expres-
sing HLA-G. We used 721.221 or Ltk cells displaying
dimeric and monomeric HLA-G identical to normal
Figure 5. LILRB1-Fc preferentially binds to the dimeric form of
HLA-G at the cell surface. 721.221 HLA-G
+ transfectants (221G),
untransfected controls (221P) and normal trophoblast cells
were surface-biotinylated, immunoprecipitated with the in-
dicated antibodies or fusion proteins and resolved by non-
reducing PAGE before Western blotting with streptavidin-HRP.
These results are representative of five different experiments
for each cell type. Trophoblast cells were pooled from
15 samples. The image includes lanes from separate gels.
Figure 4.LILRB1-FcbindstoHLA-Gat thesurfaceoftransfected
cells and trophoblast. HLA-G expression on the indicated cells
was detected by G233 staining (green) compared to untrans-
fected cells (red) or with an isotype control mAb (filled
histogram) (A–D). LILRB1 binding to the indicated cells was
detected by LILRB1-Fc staining (green) compared to untrans-
fected cells (red) or with an IgG-Fc fragment (filled histogram)
(E–H). Specificity was confirmed with blocking mAb (J–M):
LILRB1-Fc (green) and IgG1-Fc fragment (filled histogram)
binding are shown as before and also after pre-incubation of
the fusion protein with anti-LILRB1 mAb M401 (red) or of the
cells with anti-HLA-I mAb W6/32 (blue). These results are
representative of four different experiments for each cell type,
usingtrophoblastfromeightsamples.ToseeLILRB1-Fcbinding
to trophoblast cells, contaminating leukocytes that bound the
fusion protein non-specifically via FccR were labelled with a
lineage marker cocktail (CD3/14/16/19/20/56-FITC) and analy-
sis was performed on FITC-negative trophoblast cells (upper
left quadrant). Dot plots of LILRB1-Fc binding (N) and blocking
by anti-LILRB1 mAb (O) are shown.
Eur. J. Immunol. 2007. 37: 1924–1937 Immunomodulation 1929
f 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eutrophoblast and untransfected cells as controls. MDDC
maturation was stimulated by TLR4 ligand (LPS),
inflammatory cytokines (TNF-a, IL-6 and IL-1b)o r
soluble CD40 ligand. During MDDC differentiation,
HLA-G was presented either concomitantly with the
maturation stimulus or preceding it. The results were
essentially similar. MDDC expressed the LILRB1 and B2
receptors, and these were down-regulated in co-culture
with cells expressing HLA-G but not with control cells
(Fig. 6A). This is consistent with an interaction
occurring between the LILR and HLA-G. HLA-DR,
costimulatory molecules (CD40, CD80, CD86) and the
activation marker CD83 were up-regulated on MDDC in
response to all three maturation stimuli (Fig. 6A). Up-
regulation of these markers was not affected by HLA-G
and is consistent with maturation to an antigen-
presenting phenotype. However, analysis of the cyto-
kines produced by these activated MDDC did show
changes when HLA-G was present. MDDC activated in
the presence of HLA-G demonstrated a significant
increase in IL-6 and IL-10 production (p = 0.04 and
p = 0.01, respectively) (Fig. 6B). In contrast, there was
no effect on TNF-a (Fig. 6B) or IL-8 secretion (not
shown). These experiments indicate that when DC are
activated, although HLA-G does not affect the acquisi-
tion of maturation markers, it does alter their cytokine
secretion by increasing IL-6 and IL-10 production.
HLA-GstimulatingLILRBonHLA-DR
+cellsresults
in inhibited allogeneic lymphocyte proliferation
We next investigated how DC exposed to HLA-G would
function in the presentation of allogeneic stimuli to
Tcells. Previously, the presence of HLA-G in an MLR has
Figure 6. MDDC activated in the presence of HLA-G show normal up-regulation of maturation markers but altered cytokine
production. (A) MDDC, co-cultured with HLA-I null 721.221 cells, were analysed for expression of the indicated LILR receptors,
differentiation and activation markers in the absence of stimulation (filled histogram) or after exposure to LPS (green trace). The
same markers were analysed after exposure to LPS in the presence of HLA-G transfectants instead of HLA null cells (red trace).
Isotype control staining foreach marker is shown in orange.(B) Levels of the indicated cytokines in these co-culture supernatants
weremeasuredbyELISAontwo separate occasions. Arepresentativeexperiment isshown here, SDoftriplicatemeasurements.
Culture supernatants from at least four independent experiments were tested and analysed together for statistical significance.
Richard Apps et al. Eur. J. Immunol. 2007. 37: 1924–1937 1930
f 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eubeen shown to result in reduced responder T cell
proliferation [34–36]. Most reports infer that HLA-G is
directly inhibiting T cells, although a molecular
mechanism has not been defined as HLA-G-restricted
TCR have not been described in humans [34, 35]. Given
the strong binding of dimeric HLA-G to LILRB1 and the
observed increased IL-6 and IL-10 production by MDDC
exposed to HLA-G, we sought to determine whether it is
the interaction between trophoblast HLA-G and LILRB
on antigen-presenting cells (APC) that results in down-
regulation of allogeneic T cell proliferation.
Wetherefore establishedaone-wayMLRusing PBMC
as responders and 721.221 cells as stimulators. The
stimulators were either HLA-I null (parent), HLA-G1
transfectants expressing HLA-G dimers as well as
monomers, or HLA-C transfectants to control for the
effect of a conventional HLA-I molecule. At a 1 : 1
stimulator/responder ratio, the presence of HLA-G
reduced the alloproliferative response compared to
the parent cell line, by a magnitude consistent with
previous reports (p = 0.03) (Fig. 7A) [34–36]. In
contrast, a marginally increased response was seen
Figure 7. Allogeneic lymphocyte proliferation is inhibited by HLA-G interacting with LILRB receptors on HLA-DR
+ cells.
(A) Irradiated 721.221 stimulator cells transfected with various HLA-I molecules were cultured with PBMC responders from a
healthydonor. Proliferationmeasuredby [
3H]thymidineincorporationafter5 dayswas reducedinthepresenceofHLA-Gbutnota
classical HLA-I molecule. Reduced proliferation to HLA-G transfectants was abrogated by addition of anti-LILRB and anti-HLA-I
mAb. (B) When HLA-DR
+ cells were depleted from the responder population, a reduced proliferative response with no additional
inhibitory effect by HLA-G was observed. One result is shown,  SD of triplicates. Three to ten independent experiments under
each condition were performed and these were analysed together for statistical significance. (C) Flow cytometry analysis of the
responder population confirming depletion of HLA-DR
+ cells.
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previous results [36],mAbspecifictoHLA-I orLILRB1/2
moleculesthatareknowntoblockHLA-G:LILRBbinding
(Fig. 4) [33, 37] reversed the inhibition of proliferation
observed in the presence of HLA-G (Fig. 7A).
To test whether HLA-DR
+ cells expressing LILRB
were responsible for the HLA-G-mediated inhibition of
proliferation, we next depleted these cells from
responder populations. In an MLR, responder T cell
proliferation results both from direct stimulation by the
allogeneic HLA of stimulator cells as well as from
indirect stimulation of allogeneic stimulator cell anti-
gens presented byresponder APC. We found that if HLA-
DR
+ cells are depleted from the responding PBMC
population (Fig. 7C), the proliferative response to the
parent cell line is reduced as expected, since only
directly reacting Tcells can respond (Fig. 7B). However,
there is no additional inhibitory effect in the presence of
HLA-G after removal of HLA-DR
+ cells from the
responding PBMC. Therefore, we conclude that HLA-G
only inhibits the indirect APC-dependant stimulation of
proliferation. Taken together, our findings indicate that
the interaction of HLA-G dimers with LILR expressed by
HLA-DR
+ cells is directing myelomonocytic cells to
down-regulate T cell proliferative responses.
Discussion
We have shown that a significant proportion of HLA-G
molecules present at the surface of normal human
trophoblast cells in vivo exist as a dimer. Previously,
there were concerns that these dimers were merely an
artefact of overexpression in transfectants, particularly
as we and others have found that they are difficult to
detect on JEG-3 choriocarcinoma cells [17, 19]. This
homodimer is of the conventional, b2m-associated
HLA-I complex. Crystal structure [20] and mutational
studies [18] have demonstrated that the dimeric form of
HLA-G is formed by disulphide bonding between
cysteine 42 residues of the heavy chain a1 domain.
This b2m-associated dimeric complex is likely to be
unique to HLA-G, as among HLA-I molecules a cysteine
at position 42 is specific to HLA-G. HLA-B27, for
example, can also form disulphide-linked multimers in
vitro, but these are mediated by bonding between
cysteines at position 67 and require heavy chain
dissociated from b2m [22]. The unique conformation
of HLA-G as a homodimer of conventional, b2m-
associated class I complexes crucially maintains recog-
nition by the LILRB1 receptor because co-crystal
structures confirm that a significant proportion of this
receptor's interface with HLA-I molecules is with the
b2m molecule [15]. In healthy individuals, HLA-G
expression is restricted to fetal trophoblast cells that
invade the uterine decidua and myometrium in
placentation [11]. It is possible that HLA-G dimers
could act as a pregnancy-specific signal modulating the
local uterine immune response.
The HLA-G dimers we have demonstrated at the
surface of EVT will come into contact with virtually all
the maternal leukocytes of the decidua [11]. The
dominant population of NK cells may bind endocytosed
HLA-G via KIR2DL4 [12], although it is not known if
HLA-G dimerisation affects KIR2DL4 binding. In con-
trast, preferential binding of the HLA-G dimers to LILR
molecules has been well described. The inhibitory
receptors, LILRB1 and LILRB2, both bind all HLA-I
molecules, with a higher affinity for HLA-G attributed to
sequence differences in the a3 domain [16]. HLA-G free
heavy chains observed at the surface of transfectants
reduce LILRB1 binding to b2m-associated HLA-G
complexes and potentially modulate LILRB1 stimulation
[19]. Recently, the increased avidity of HLA-G dimer-
isation has been shown to substantially increase binding
to LILRB. A LILRB1-Fc fusion protein bound more
strongly to wild-type HLA-G than to HLA-G where the
cysteineis mutatedtoaserine atposition 42, abrogating
dimerisation [18, 19]. This was supported by surface
plasmon resonance measurements of recombinant
monomeric and dimeric HLA-G complexes binding
LILRB molecules [20]. The increased binding avidity
of HLA-G dimers translates into augmented signalling
through LILRB1. This was shown by LILRB1-mediated
inhibition of serotonin release triggered by IgeR,
inhibition of NK killing [18] and a LILRB1 chimera
NFAT-GFP reporter cell assay [20].
We therefore investigated LILR expression in the
decidua and binding to HLA-G dimers on trophoblast
cells. Previous studies in humans have only demon-
strated binding of HLA-G tetramers to peripheral
myelomonocytic cells [38]. We detected LILRB1 and
B2 expression by all decidual HLA-DR
+ cells, consistent
with results detecting expression on decidual macro-
phages [39]. In contrast to peripheral myelomonocytic
cells, LILRB1 and not LILRB2 appears to be predomi-
nantly expressed in the decidua. LILRB1 was also
detectedon 20% of NK and 10% of Tcells in the decidua.
This is similar tothe expressiononperipheral PBMC [13,
40], although the function of LILRB1 on these other
leukocytes remains unclear.
Having detected LILRB expression by decidual
myelomonocytic cells, we demonstrated binding of
LILRB1-Fc fusion proteins to HLA-G at the surface of
normal trophoblast cells. The specificity of this interac-
tion was confirmed by blocking mAb to both LILRB1 and
HLA-I molecules. In keeping with the previous findings
that LILRB1 preferentially binds to HLA-G dimers, no
binding was demonstrable with JEG-3 cells that mainly
displayed conventional monomeric HLA-G. A more
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tially with HLA-G dimers on trophoblast cells was shown
by the LILRB1-Fc fusion protein predominantly im-
munoprecipitating dimeric HLA-G from normal tropho-
blast cells. These results indicate that LILRB1 would
mainly bind dimeric HLA-G on the trophoblast in vivo,
which could represent a mechanism allowing LILRB1
+
decidual APC to discriminate between the fetal tropho-
blast and maternal cells expressing conventional HLA-I
molecules.
We have shown that soluble HLA-G5 immunopreci-
pitated from the culture supernatant of transfected cells
canalsoformab2m-associateddimer.However,wewere
notabletoimmunoprecipitateanyformofsolubleHLA-G
fromculturesupernatantsofprimarytrophoblastcellsor
pre-implantation embryos, consistent with previous
reports describing only very low levels of HLA-G5
transcripts [3, 4] and shed HLA-G1 protein in vivo [4].
We next investigated the possible function of cell
surface HLA-G dimers stimulating LILRB1 on myelo-
monocytic cells in the decidua. As shown previously, in
the presence of HLA-G, MDDC still responded to various
activation stimuli to mature to an antigen-presenting
phenotype [41]. Another study did show a slight
reduction in DC maturation markers in the presence
of HLA-G tetramers [42], although IL-10 was used
during MDDC differentiation in this study and is known
to inhibit MDDC maturation [43, 44]. In addition to
immature DC, antigen presentation by activated DC can
alsoresultinsuppressionofadaptiveimmuneresponses,
an effect likely to be mediated by concomitant cytokine
production [45, 46]. Therefore, we measured cytokine
production and found that induction of IL-6 and IL-10
was increased by MDDC activated in co-culture with
HLA-G
+ compared to HLA-I null transfectants, whereas
inflammatory cytokines such as TNF-a were unaffected.
IL-10 has a well characterised role as an immunosup-
pressive cytokine and has been implicated in the
function of regulatory T cells [47]. IL-6 is pleiotropic,
but has also been shown to have immunosuppressive
effects with DC [48]. Indeed, non-inflammatory gut
mucosal DC co-cultured with intestinal epithelial cells
produce IL-6 and IL-10 even in the presence of a
pathogen [49]. This situation has clear resonance with
the local environment in the uterine mucosa where DC
are exposed to infiltrating HLA-G
+ trophoblast cells.
These results are also consistent with observations from
the myelomonocytic cell line U937, which increased
IL-10 and TGF-b1 production after treatment with
HLA-G [50].
The most likely functional effect of HLA-G dimers on
trophoblast binding todecidual HLA-DR
+ cells wouldbe
down-regulation of damaging maternal Tcell responses
to allogeneic placental cells. Indeed, in keeping with
previous reports, we observed a diminished proliferative
response of allogeneic lymphocytes when HLA-G,
compared to classical HLA-I molecules, were present
on stimulator cells [34–36]. Our findings indicate that
HLA-G is mediating the inhibitory effect on lymphocyte
proliferationbybindingtoLILRB1 andB2onresponding
APC. By removal of HLA-DR
+ cells from the responder
population, we found that HLA-G had no effect on the
direct Tcell response. This observation is highly relevant
to the situation in vivo because trophoblast cells do not
express allogeneic HLA-A, HLA-B or HLA-II molecules
that could be perceived directly by maternal Tcells [24].
Thus, in vivo, T cell recognition of any allogeneic
trophoblast- or placenta-specific molecules is likelytobe
via indirect presentation by decidual HLA-DR
+ cells.
There is increasing evidence for the role of LILRB in
inducing tolerogenic DC [42, 51–53], and our study
demonstrates how this interaction has particular
relevance to the placental bed, the only site where
HLA-G dimers are physiologically abundant. There are
potential parallels with mechanisms of other immuno-
priviledgedsites,wheretissue-specificmoleculessuchas
thymic stromal lymphopoietin and vasoactive intestinal
peptide modulate DC function [49, 54, 55]. We have
only studied the functional effect of DC exposed to
HLA-G on allogeneic lymphocyte proliferation. How-
ever, the altered cytokine production of these DC may
also modulate uterine NK cell function [56]. HLA-G has
now been shown to interact with both NK cells [12] and
HLA-DR
+ cells, together accounting for *90% of the
leukocytes at the placental implantation site [11]. Thus,
as placental trophoblast cells infiltrate the uterine
mucosa, they can deliver a pregnancy-specific signal
tomostof thelocalmaternalleukocytesandmodifytheir
function to accommodate the feto-placental unit [57].
Materials and methods
Cell lines and primary tissue
Thecelllinesusedwere:humanB lymphoblastoid721.221line
transfectedwithHLA-C[58],HLA-G5[28]orHLA-G1mutated
in the leader sequence to abrogate HLA-E expression [14];
murine Ltk cells transfected either with human b2m alone or
with b2m and HLA-G together [59]; and the choriocarcinoma
cell line JEG-3 (ATCC, Rockville, MD). Decidual and placental
tissues were obtained from elective terminations of normal
first-trimester pregnancies. Ethical approval for the use of
these tissues was obtained from the Cambridge Local Research
Ethics Committee. Decidual leukocytes and trophoblast cells
were isolated as described [25]. Briefly, decidual tissue was
disaggregated with collagenase and mononuclear cells were
purified on Lymphoprep. The trophoblast was released from
the chorionic villi by trypsin digestion and macrophages were
depleted by adherence to plastic. After culture overnight on
fibronectin, 50–80% of trophoblast cells label HLA-G
+ by flow
cytometry with the mAb G233 [2].
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Conformationally dependant mAb specific for HLA-G were
G233 [2] from our laboratory, 87G [60] from Dr. D.
Geraghty, and MEM-G/11 [61] from AbCam. BBM.1 (Santa
Cruz Biotechnology) specifically recognises b2m [62], W6/32
(Serotec) binds molecules encoded by all HLA-I loci [63],
T 149 (from Dr. B. Uchanska-Ziegler) and B1.23.2 (from
Dr. P. Le Bouteiller) recognise HLA-B and HLA-C allotypes
[23, 64]. MEM-G/1 (Abcam) detects denatured HLA-G [65].
Anti-LILRB1 (M401) and anti-LILRB2 (M422) mAb [66]
were supplied by Amgen Inc. Different anti-LILRB1 mAb
(HP-F1) [37] and anti-LILRB2 mAb (42D1) [67] were from
Dr. M. Lopez-Botet and Dr. M. Colonna, respectively. Isotype
control antibodies were from Oxford Biotechnology. A
sequenced LILRB1-Fc fusion protein construct [66] from
Amgen Inc was transiently transfected into 293T cells using
Lipofectamine 2000 (Invitrogen). Fusion protein was puri-
fied from supernatant with protein G-Sepharose beads
(Amersham Pharmacia Biotech) and assayed by Easy-Titer
(Pierce) and reducing SDS-PAGE, where it resolved as a
single band at *100 kDa.
Biotinylation, immunoprecipitation, PAGE and Western
blotting
Cells were washed with cold PBS, then biotinylated with
0.2 mg/mL EZ-Link Sulfo-NHS-LC-Biotin (Pierce) in pH 8.0
PBS for 30 min at 4
C to prevent endocytic intracellular
labelling. Unconjugated reagent was quenched by adding
glycine to a concentration of 10 mM. Cells were then lysed in
fresh ONYX lysis buffer [20 mM Tris (pH 7.4), 140 mM NaCl,
1 mM EGTA, 1% Triton, 10% glycerol, 50 mM iodoacetamide
and protease inhibitor cocktail (Roche)]. This concentration of
iodoacetamide has been shown to prevent post-lysis HLA-I
multimerisation [30]. Labelled lysates were stored at –80
C.
Thawd lysates were incubated for 90 min at 4
C with
protein G-Sepharose beads coated with isotype control mAb.
Precleared lysates were then immunoprecipitated for 90 min
at 4
C with protein G-Sepharose beads precoated with anti-
HLA antibodies or LILRB1-Fc. Immunoprecipitates were
washed with ONYX containing 3 mM SDS, bound proteins
were eluted with NuPAGE LDS Sample Buffer (Invitrogen) and
divided into two aliquots; one was denatured by treatment at
95
C for 10 min, the other was denatured and reduced by the
same process in the presence of 200 mM 2-mercaptoethanol
(Sigma). Denatured samples were stored at –20
C overnight.
For immunoprecipitation of soluble HLA-G, transfected
721.221 cell cultures were inoculated at 1  10
6 cells/mL
and incubated for 2 days. JEG-3 and primary trophoblast cells
were cultured as described for 2 days [2, 25]. Human pre-
implantation embryo culture supernatants were obtained from
Dr. R. Gosden (Cornell University). Supernatants were
concentrated by centrifugal filtration if necessary (Amicon,
30 000 MWCO) and a 700-lL aliquot was precleared as before
and immunoprecipitated overnight.
Samples were resolved on reducing or non-reducing
NuPAGE Bis-Tris 10% gels (Invitrogen), electroblotted and
visualised with a streptavidin-HRP conjugate followed by ECL
detection (Amersham Biosciences). Unlabelled soluble HLA-G
molecules were detected with biotinylated MEM-G/1 followed
by streptavidin-HRP. 2D-PAGE was performed by running a
non-reducing gel as above, excising the lane and equilibrating
for 30 min in reducing buffer (0.125 M Tris pH 8, 3.5 mM
SDS, 0.15 M 2-mercaptoethanol). This gel slice was then
positioned at 90
 along the top of a new gel and run under
reducing conditions before Western blotting as above.
Flow cytometry
Freshly isolated leukocytes were first incubated with human
IgG (Sigma) to block Fcc receptors. Anti-LILRB1 and -LILRB2
antibodies were added and detected with fluorochrome-
conjugated secondary antibodies. Free secondary antibody
binding sites were blocked with the appropriate species Ig,
beforestainingwithdirectlyconjugatedCD56,CD3orHLA-DR
mAb(SerotecandBectonDickinson).Datawasacquiredwitha
FACScan flow cytometer and analysed using CellQuest soft-
ware (Becton Dickinson).
Primary trophoblast cells cultured overnight were removed
from the plate with 0.5 mM EDTA. Fcc receptors were blocked
with 40% heat-inactivated human AB serum (Sigma) for G233
mAb staining experiments or with mouse anti-CD32 antibody
(Stem Cell Technologies) for LILRB1-Fc staining experiments.
Contaminating fetal leukocytes were also labelled with lin-
FITC, a cocktail of FITC-conjugated anti-CD3, -CD14, -CD16,
-CD19, -CD20 and -CD56 antibodies (Becton Dickinson). Cells
were stained with G233 mAb, LILRB1-Fc or IgG1-Fc fragment
(Bethyl Laboratories). Primary antibody was detected with PE-
conjugated anti-mouse IgG F(ab')2 fragment (Sigma). Fusion
protein binding was detected with PE-conjugated anti-human
IgG(c chainspecific) secondaryantibody(Sigma).Inblocking
experiments, fusionproteinwas incubated with anti-LILRB1 or
isotypecontrolantibodyorcellswereincubatedwithW6/32or
the isotype control antibody prior to staining with fusion
protein.
MDDC experiments
PBMC from healthy donor buffy coats were isolated on
Lymphoprep (Axis-Shield, Norway), washed extensively and
plated in plastic culture dishes at 2  10
7 cells/mL. After 2 h,
non-adherent cells were washed away and the adherent
fraction was cultured in RPMI with GM-CSF (100 ng/mL) and
IL-4 (40 ng/mL) (Biosource), refreshing the medium as
necessary. After 5 days, more than 80% of the cells exhibited
a DC-like phenotype (LILRB4
+, DC-SIGN
+, CD14
–) with fewer
than 10% of cells CD3
+. MDDC were stimulated for 12–24 h
with 10 ng/mL LPS (Sigma), 500 ng/mL sCD40L (Peprotech)
or 20 ng/mL TNF-a, 50 ng/mL IL-6 and 10 ng/mL IL-1b
(Biosource, R&D Systems). HLA-I null 721.221 or Ltk parent
andHLA-G-transfectedcellswereirradiatedwith1000 radand
added to the MDDC either with the maturation stimulus or
throughout their differentiation.
Cells were harvested and stained for flow cytometry with
LILRB4-PC5 (Becton Dickinson), PE-conjugated antibodies to
CD14 (Becton Dickinson), CD40, CD80, CD83 and CD86 (all
Serotec), FITC-conjugated HLA-DR antibody (Becton Dick-
inson) and unlabelled DC-SIGN (Becton Dickinson), anti-
LILRB1 (M401) and -LILRB2 (M422) antibodies followed by
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analysed for IL-6, IL-8, IL-10 and TNF-a by ELISA (R&D
Systems).
Mixed lymphocyte reaction
Stimulator cells were 721.221 parent (5) or HLA-G1 (105),
HLA-G5 and HLA-C (80) transfectants. The HLA-I-transfected
cells had similar levels of expression as monitored by BBM.1
staining; the MFI is shown in parentheses above. Stimulator
cells were washed, seeded at equal densities and cultured
overnight without selection. These cells were then irradiated
with 5000 rad and aliquoted into wells of a 96-well plate at
varying densities to give stimulator/responder ratios of
between 3 : 1 and 0.1 : 1. Responder cells were PBMC from
healthy donors, isolated on Lymphoprep and added at
5  10
4 cells/well in a total volume of 300 lL. All donors
demonstrated proliferation and when typed retrospectively
where shown to be mismatched to the HLA-DR1 epitope
expressed by 721.221 cells [58]. Donors in the experiments
shown in Fig. 7 were DRB1*04/DRB1*07 in panel (A) and
DRB1*03/DRB1*13 in panel (B). HLA-DR
+ cells were re-
moved from responder populations with azide-free HLA-DR-
FITC and EasySep FITC-selection kit (Stem Cell Technologies).
After 5 days, 1 lCi/well of [
3H]thymidine was added, cells
were harvested after a further 18 h (TomTec 96-well plate
harvester), and [
3H]thymidine incorporation was measured
(Wallac Trilux liquid scintillation counter). For blocking
experiments, azide-free HP-F1 (3 lL ascites/well), M401,
M422 or W6/32 (all 0.05 lg/well) were added immediately.
F(ab')2 fragments of W6/32, necessary to avoid antibody-
dependant cell-mediated cytotoxicity, were generated by
pepsin digestion [68].
Statistical analysis
For MDDC cytokine production and MLR proliferation
experiments, means of replicates of a sample were compared
in the presence and absence of HLA-G by two-tailed paired
Student's t-test for the total number of independent times the
experiments were run. Calculations were performed using
InStat software, with a p value <0.05 regarded as significant.
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